Aptus Capital Advisors’s Ocular Therapeutix OCUL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5.04M Buy
656,908
+18,217
+3% +$178K 0.03% 387
2026
Q2
$6.27M Buy
638,691
+108,912
+21% +$987K 0.04% 322
2026
Q1
$4.49M Buy
529,779
+29,027
+6% +$277K 0.04% 356
2025
Q4
$6.08M Buy
500,752
+98,285
+24% +$1.19M 0.04% 301
2025
Q3
$4.7M Buy
402,467
+17,000
+4% +$203K 0.03% 328
2025
Q2
$3.58M Buy
385,467
+39,369
+11% +$308K 0.03% 342
2025
Q1
$2.54M Buy
346,098
+6,348
+2% +$48.8K 0.03% 365
2024
Q4
$2.9M Buy
339,750
+76,940
+29% +$751K 0.03% 343
2024
Q3
$2.29M Hold
262,810
– – 0.03% 306
2024
Q2
$1.8M Buy
+262,810
New +$1.62M 0.03% 307

Other funds holding OCUL

Aptus Capital Advisors's OCUL Position: Q3 2026 in Review

Aptus Capital Advisors increased its Ocular Therapeutix (OCUL) stake by 2.9% in Q3 2026, buying an estimated $178K and bringing the position to 656,908 shares worth $5.04M. The position accounts for 0.03% of the portfolio, ranked #387.

Aptus Capital Advisors first reported a position in OCUL in Q2 2024 and has held it in 10 quarters since. The position peaked at $6.27M in Q2 2026. 263 funds tracked by Wall St. Rank hold OCUL as of Q3 2026.

  • Aptus Capital Advisors held 656,908 shares of Ocular Therapeutix worth $5.04M as of Q3 2026.
  • Aptus Capital Advisors bought 18,217 Ocular Therapeutix shares in Q3 2026, an estimated $178K.
  • Ocular Therapeutix made up 0.03% of Aptus Capital Advisors's portfolio in Q3 2026, its #387 holding.
  • Aptus Capital Advisors first reported a position in Ocular Therapeutix in Q2 2024 and has held it in 10 quarters since.
  • Aptus Capital Advisors's Ocular Therapeutix position peaked at $6.27M in Q2 2026.
  • 263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2026.

Based on Aptus Capital Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.